View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPierrel 将来の成長Future 基準チェック /06現在、 Pierrelの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.80, the stock trades at a trailing P/E ratio of 30.6x. Average trailing P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 35% over the past three years.New Risk • Oct 08New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 29% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (91% net debt to equity). Large one-off items impacting financial results. Market cap is less than US$100m (€87.9m market cap, or US$93.1m).New Risk • Sep 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (81% net debt to equity). Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (€87.3m market cap, or US$93.0m).New Risk • Sep 10New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (81% net debt to equity). Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (€86.0m market cap, or US$92.0m).New Risk • Aug 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (81% net debt to equity). Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (€85.4m market cap, or US$93.9m).お知らせ • Aug 02Pierrel S.p.A. (BIT:PRL) completed the acquisition of assets associated with Dental local anesthetic business from 3M Company (NYSE:MMM) for $70 million.Pierrel S.p.A. (BIT:PRL) entered into agreements to acquire assets associated with Dental local anesthetic business from 3M Company (NYSE:MMM) for $70 million on May 2, 2023. The purchase consideration payable in cash, is subject to closing and other adjustments. These local anesthetic products had annual sales in 2022 of approximately $30 million. The transaction, which is subject to information or consultation requirements with relevant works councils and other closing conditions, is expected to be completed in the third quarter of 2023. The impact of ongoing operations were not material to 3M's financial results.Pierrel S.p.A. (BIT:PRL) completed the acquisition of assets associated with Dental local anesthetic business from 3M Company (NYSE:MMM) for $70 million. on August 1, 2023.Valuation Update With 7 Day Price Move • Jul 11Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €2.22, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 12% over the past three years.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Aug 07Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €4.83m (up 12% from 2Q 2021). Net loss: €1.00m (loss widened 329% from 2Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 5.4% growth forecast for the industry in Germany.Reported Earnings • Jun 11First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: €5.99m (down 8.1% from 1Q 2021). Net income: €542.0k (down 42% from 1Q 2021). Profit margin: 9.1% (down from 14% in 1Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.0% growth forecast for the industry in Germany.Reported Earnings • May 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €23.8m (up 30% from FY 2020). Net income: €2.94m (up 55% from FY 2020). Profit margin: 12% (up from 10% in FY 2020). The increase in margin was driven by higher revenue.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 18Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €4.96m (up 96% from 3Q 2020). Net income: €673.0k (up €1.31m from 3Q 2020). Profit margin: 14% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.Reported Earnings • Apr 30First quarter 2021 earnings released: EPS €0.004 (vs €0.003 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: €6.52m (up 27% from 1Q 2020). Net income: €940.0k (up 34% from 1Q 2020). Profit margin: 14% (in line with 1Q 2020).Reported Earnings • Mar 13Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €18.3m (down 17% from FY 2019). Net income: €1.90m (down 15% from FY 2019). Profit margin: 10% (in line with FY 2019).Is New 90 Day High Low • Feb 26New 90-day high: €0.23The company is up 56% from its price of €0.15 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period.Is New 90 Day High Low • Feb 17New 90-day high: €0.22The company is up 51% from its price of €0.14 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.Reported Earnings • Nov 16Third quarter 2020 earnings released: €0.003 loss per shareThe company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: €2.54m (down 54% from 3Q 2019). Net loss: €634.0k (down 489% from profit in 3Q 2019).お知らせ • Sep 22Gianluca Vacchi acquired 2% stake in Pierrel SpA.Gianluca Vacchi acquired 2% stake in Pierrel SpA on January 10, 2007. Gianluca Vacchi completed the acquisition of 2% stake in Pierrel SpA on January 10, 2007.Reported Earnings • Sep 19First half earnings releasedOver the last 12 months the company has reported total profits of €3.76m, up 252% from the prior year. Total revenue was €22.7m over the last 12 months, up 7.8% from the prior year. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Pierrel は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:2FJ0 - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2023273-48N/A3/31/2023251N/AN/AN/A12/31/2022241-37N/A9/30/2022251N/AN/AN/A6/30/2022242-96N/A3/31/2022233N/AN/AN/A12/31/2021243-57N/A9/30/2021213N/AN/AN/A6/30/2021191-15N/A3/31/2021213N/AN/AN/A12/31/2020182-13N/A9/30/2020203N/AN/AN/A6/30/202023404N/A3/31/2020212N/AN/AN/A12/31/2019222-22N/A9/30/2019221N/AN/AN/A6/30/201921103N/A3/31/2019211N/AN/AN/A12/31/201820101N/A9/30/2018212N/AN/AN/A6/30/2018202-2-1N/A3/31/2018190N/AN/AN/A12/31/201717-3-2-1N/A9/30/201715-8N/AN/AN/A6/30/201714-9-2-2N/A3/31/201714-8N/AN/AN/A12/31/201615-6N/A-2N/A9/30/201614-2N/AN/AN/A6/30/201614-1N/A-8N/A3/31/2016150N/AN/AN/A12/31/2015160N/A-8N/A9/30/2015510N/AN/AN/A6/30/201586N/A-4N/A3/31/2015130N/AN/AN/A12/31/201415-2N/A-8N/A9/30/201430-16N/AN/AN/A6/30/201429-16N/A-10N/A3/31/201429-12N/AN/AN/A12/31/201330-13N/A-10N/A9/30/201330-14N/AN/AN/A6/30/201336-12N/A-8N/A3/31/201340-13N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 2FJ0の予測収益成長が 貯蓄率 ( 0.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 2FJ0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 2FJ0の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 2FJ0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 2FJ0の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 2FJ0の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/01/28 05:54終値2024/01/26 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pierrel S.p.A. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Luigi TardellaEnVent Capital Markets LimitedFabrizio BariniIntermonte SIM S.p.A.
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.80, the stock trades at a trailing P/E ratio of 30.6x. Average trailing P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 35% over the past three years.
New Risk • Oct 08New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 29% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (91% net debt to equity). Large one-off items impacting financial results. Market cap is less than US$100m (€87.9m market cap, or US$93.1m).
New Risk • Sep 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (81% net debt to equity). Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (€87.3m market cap, or US$93.0m).
New Risk • Sep 10New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (81% net debt to equity). Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (€86.0m market cap, or US$92.0m).
New Risk • Aug 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (81% net debt to equity). Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (€85.4m market cap, or US$93.9m).
お知らせ • Aug 02Pierrel S.p.A. (BIT:PRL) completed the acquisition of assets associated with Dental local anesthetic business from 3M Company (NYSE:MMM) for $70 million.Pierrel S.p.A. (BIT:PRL) entered into agreements to acquire assets associated with Dental local anesthetic business from 3M Company (NYSE:MMM) for $70 million on May 2, 2023. The purchase consideration payable in cash, is subject to closing and other adjustments. These local anesthetic products had annual sales in 2022 of approximately $30 million. The transaction, which is subject to information or consultation requirements with relevant works councils and other closing conditions, is expected to be completed in the third quarter of 2023. The impact of ongoing operations were not material to 3M's financial results.Pierrel S.p.A. (BIT:PRL) completed the acquisition of assets associated with Dental local anesthetic business from 3M Company (NYSE:MMM) for $70 million. on August 1, 2023.
Valuation Update With 7 Day Price Move • Jul 11Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €2.22, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 12% over the past three years.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 07Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €4.83m (up 12% from 2Q 2021). Net loss: €1.00m (loss widened 329% from 2Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 5.4% growth forecast for the industry in Germany.
Reported Earnings • Jun 11First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: €5.99m (down 8.1% from 1Q 2021). Net income: €542.0k (down 42% from 1Q 2021). Profit margin: 9.1% (down from 14% in 1Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.0% growth forecast for the industry in Germany.
Reported Earnings • May 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €23.8m (up 30% from FY 2020). Net income: €2.94m (up 55% from FY 2020). Profit margin: 12% (up from 10% in FY 2020). The increase in margin was driven by higher revenue.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 18Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €4.96m (up 96% from 3Q 2020). Net income: €673.0k (up €1.31m from 3Q 2020). Profit margin: 14% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.
Reported Earnings • Apr 30First quarter 2021 earnings released: EPS €0.004 (vs €0.003 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: €6.52m (up 27% from 1Q 2020). Net income: €940.0k (up 34% from 1Q 2020). Profit margin: 14% (in line with 1Q 2020).
Reported Earnings • Mar 13Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €18.3m (down 17% from FY 2019). Net income: €1.90m (down 15% from FY 2019). Profit margin: 10% (in line with FY 2019).
Is New 90 Day High Low • Feb 26New 90-day high: €0.23The company is up 56% from its price of €0.15 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Feb 17New 90-day high: €0.22The company is up 51% from its price of €0.14 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.
Reported Earnings • Nov 16Third quarter 2020 earnings released: €0.003 loss per shareThe company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: €2.54m (down 54% from 3Q 2019). Net loss: €634.0k (down 489% from profit in 3Q 2019).
お知らせ • Sep 22Gianluca Vacchi acquired 2% stake in Pierrel SpA.Gianluca Vacchi acquired 2% stake in Pierrel SpA on January 10, 2007. Gianluca Vacchi completed the acquisition of 2% stake in Pierrel SpA on January 10, 2007.
Reported Earnings • Sep 19First half earnings releasedOver the last 12 months the company has reported total profits of €3.76m, up 252% from the prior year. Total revenue was €22.7m over the last 12 months, up 7.8% from the prior year.